Insulet Co. (NASDAQ:PODD) Holdings Lifted by Empowered Funds LLC

Empowered Funds LLC raised its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 357.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,327 shares of the medical instruments supplier's stock after purchasing an additional 3,381 shares during the quarter. Empowered Funds LLC's holdings in Insulet were worth $1,130,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of PODD. Blue Trust Inc. grew its stake in Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 58 shares in the last quarter. Venturi Wealth Management LLC grew its stake in Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after purchasing an additional 133 shares in the last quarter. TD Private Client Wealth LLC grew its stake in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock valued at $53,000 after purchasing an additional 56 shares in the last quarter. Friedenthal Financial acquired a new stake in Insulet during the 4th quarter valued at approximately $57,000. Finally, Versant Capital Management Inc grew its stake in Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier's stock valued at $80,000 after purchasing an additional 157 shares in the last quarter.

Insulet Stock Performance

Insulet stock traded up $4.61 during mid-day trading on Thursday, hitting $288.29. 847,254 shares of the company's stock traded hands, compared to its average volume of 548,348. The firm has a 50 day moving average price of $272.37 and a 200 day moving average price of $246.18. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company has a market cap of $20.22 billion, a PE ratio of 49.36, a price-to-earnings-growth ratio of 3.52 and a beta of 1.23. Insulet Co. has a one year low of $160.19 and a one year high of $289.46.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 27.98% and a net margin of 21.22%. On average, equities analysts forecast that Insulet Co. will post 3.22 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on PODD. Canaccord Genuity Group lifted their target price on Insulet from $269.00 to $304.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. Barclays lifted their target price on Insulet from $220.00 to $234.00 and gave the stock an "equal weight" rating in a research report on Monday, November 11th. Citigroup lifted their target price on Insulet from $283.00 to $310.00 and gave the stock a "buy" rating in a research report on Wednesday, December 11th. Sanford C. Bernstein began coverage on Insulet in a research report on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 target price for the company. Finally, TD Cowen lifted their target price on Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a research report on Friday, January 3rd. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, Insulet currently has a consensus rating of "Moderate Buy" and an average price target of $277.13.

Insider Activity

In related news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. The trade was a 13.76 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is owned by insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.